CAH vs. COR, MCK, STE, ZBH, PHG, BNTX, WST, ICLR, WAT, and ARGX
Should you be buying Cardinal Health stock or one of its competitors? The main competitors of Cardinal Health include Cencora (COR), McKesson (MCK), STERIS (STE), Zimmer Biomet (ZBH), Koninklijke Philips (PHG), BioNTech (BNTX), West Pharmaceutical Services (WST), ICON Public (ICLR), Waters (WAT), and argenx (ARGX). These companies are all part of the "medical" sector.
Cencora (NYSE:COR) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.
Cencora has higher revenue and earnings than Cardinal Health. Cencora is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.
Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. Cardinal Health pays an annual dividend of $2.00 per share and has a dividend yield of 2.0%. Cencora pays out 22.3% of its earnings in the form of a dividend. Cardinal Health pays out 88.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Cencora has raised its dividend for 14 consecutive years and Cardinal Health has raised its dividend for 27 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
In the previous week, Cardinal Health had 11 more articles in the media than Cencora. MarketBeat recorded 13 mentions for Cardinal Health and 2 mentions for Cencora. Cencora's average media sentiment score of 0.58 beat Cardinal Health's score of 0.34 indicating that Cardinal Health is being referred to more favorably in the news media.
Cardinal Health received 165 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 71.66% of users gave Cardinal Health an outperform vote while only 65.12% of users gave Cencora an outperform vote.
Cencora has a net margin of 0.67% compared to Cencora's net margin of 0.25%. Cardinal Health's return on equity of 268.67% beat Cencora's return on equity.
97.5% of Cencora shares are owned by institutional investors. Comparatively, 87.2% of Cardinal Health shares are owned by institutional investors. 15.8% of Cencora shares are owned by company insiders. Comparatively, 0.2% of Cardinal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cencora currently has a consensus price target of $233.90, indicating a potential upside of 5.30%. Cardinal Health has a consensus price target of $107.57, indicating a potential upside of 8.57%. Given Cencora's higher possible upside, analysts plainly believe Cardinal Health is more favorable than Cencora.
Cencora has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.
Summary
Cencora beats Cardinal Health on 11 of the 20 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CAH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardinal Health Competitors List
Related Companies and Tools
